Sign In
Buy SNY
$42.37
-0.430 (-1.00%)
At Close: Jun 03, 2026
Market Today: Tech Sells Off on AI Jitters; M&A, FDA Moves and Policy Shifts
05:35pm, Thursday, 12'th Feb 2026
Guru Stock PicksAl Gore has made the following transactions:Reduce in NTNX by 46.77%Sold out in MCHPAdd in MELI by 2.52%New position in CSLKen Fisher has made t
Sanofi: CEO Leaves With Project Rejuvenation Unfinished, But Stock Undervalued
04:45pm, Thursday, 12'th Feb 2026
Sanofi reported FY net sales up >9% to €43.6bn and net income up >12% to €9.5mn. Despite strong results, Sanofi announced today it has replaced CEO Paul Hudson with former employee Belén Garijo,
Sanofi Shocker: CEO Paul Hudson Out As Board Demands 'Increased Rigor'
06:28am, Thursday, 12'th Feb 2026
Sanofi appoints Belén Garijo as CEO, Paul Hudson's tenure ends on Feb 17, 2026. Garijo will prioritize strengthening R&D and governance.
Who is Sanofi's new CEO Belén Garijo?
03:58am, Thursday, 12'th Feb 2026
French drugmaker Sanofi on Thursday appointed Belén Garijo as its new chief executive after choosing not to renew the mandate of Paul Hudson.
Sanofi Names Merck KGaA's Garijo to Replace Hudson as CEO
02:08am, Thursday, 12'th Feb 2026
Garijo steps in after the drugmaker's board of directors decided not to renew Hudson's mandate.
Sanofi appoints Belén Garijo as new CEO after deciding not to renew current CEO Hudson's mandate
01:47am, Thursday, 12'th Feb 2026
French drugmaker Sanofi said on Thursday it had appointed Belén Garijo as its new chief executive after deciding not to renew the mandate of current CEO Paul Hudson.
Press Release: Belén Garijo to become Chief Executive Officer of Sanofi
01:30am, Thursday, 12'th Feb 2026
Belén Garijo to become Chief Executive Officer of Sanofi Paris, February 12, 2026. Sanofi's Board of Directors met on February 11, 2026, and decided not to renew the Director mandate of Paul Hudson.
Sanofi: Information concerning the total number of voting rights and shares – January 2026
12:30pm, Wednesday, 11'th Feb 2026
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement
SNY's Rare Disease Drug Wins FDA Breakthrough and Japan Orphan Status
11:45am, Tuesday, 10'th Feb 2026
Sanofi wins FDA Breakthrough Therapy and Japan Orphan designations for Wayrilz in wAIHA, backed by LUMINA data and a late-stage study.
Press Release: Sanofi completes the acquisition of Dynavax
09:00am, Tuesday, 10'th Feb 2026
Sanofi completes the acquisition of Dynavax Paris, February 10, 2026. Sanofi today announced that it has completed the acquisition of Dynavax Technologies Corporation (Dynavax).
The US and Japan granted breakthrough therapy/orphan status to rilzabrutinib for wAIHA, a rare blood disorder marked by the destruction of red blood cells
Oakmark International Strategy Q4 2025 New Investments And Divestments
12:20pm, Sunday, 08'th Feb 2026
Oakmark International Strategy Q4 2025 New Investments And Divestments
Sanofi's Venglustat Meets Primary Endpoints in Gaucher Disease Study
01:01pm, Tuesday, 03'rd Feb 2026
SNY's phase III LEAP2MONO study meets all primary endpoints, with venglustat improving neurological symptoms in type 3 Gaucher disease patients.
UK industry body says Sanofi in breach over RSV therapy claims against Pfizer
08:42am, Monday, 02'nd Feb 2026
Sanofi has breached the UK pharma code of practice with unsubstantiated claims that its Beyfortus was more effective than Pfizer's RSV vaccine, the industry's self-regulatory body said on Monday, resp
Sanofi Plans Regulatory Submission For Investigational Drug For Rare Disease Despite Mixed Data From Pivotal Trials
08:30am, Monday, 02'nd Feb 2026
Sanofi reports positive phase 3 results for oral venglustat in type 3 Gaucher disease, matching standard therapy outcomes and supporting plans for global regulatory filings.
